Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Uterine (endometrial) cancer
Dostarlimab + carboplatin/paclitaxel stretches time to next therapy by ≥5 months in frontline advanced endometrial cancer
Dostarlimab, an anti-PD-1 antibody, was paired with standard carboplatin (AUC 5)–paclitaxel (175 mg/m²) for six cycles then continued as Q6-week maintenance in the phase 3 RUBY trial (ENGOT-EN6-NSGO/GOG-3031;…
NCT03981796 - Trial result
Multiple myeloma
Etentamig BCMA×CD3 Bispecific Hits 66% ORR with Half-the-Usual CRS in Triple-Class–Exposed Myeloma
Etentamig, a bivalent BCMA×CD3 T-cell engager engineered with low-affinity CD3 and a silenced Fc, was pooled across two Phase 1/1b studies (NCT03933735; NCT05650632) in relapsed/refractory multiple myeloma after ≥3…
NCT03933735 - Trial result
Multiple myeloma
Daratumumab + Carfilzomib/Lenalidomide/Dex Beats KRd Alone for Deep Remission in Newly Diagnosed Myeloma
Daratumumab, an anti-CD38 IgG1κ antibody, was added to the KRd triplet (Carfilzomib/Lenalidomide/Dex) in the randomized phase 2 ADVANCE trial (n=306 NDMM; transplant-eligible and ineligible). In 306 patients with…
- Trial result
Multiple myeloma
Elranatamab + Daratumumab/Lenalidomide Logs 92% Confirmed ORR in Transplant-Ineligible NDMM
In part 1 (dose level G) of the phase 3 MagnetisMM-6 trial (NCT05623020), 37 newly diagnosed, transplant-ineligible myeloma patients received subcutaneous elranatamab 76 mg Q4W plus daratumumab and lenalidomide. At…
NCT05623020 - Trial result
Multiple myeloma
JNJ-5322 Trispecific BCMA/GPRC5D/CD3 Antibody Delivers 100% ORR in Target-Naïve R/R Myeloma
JNJ-79635322 (JNJ-5322) is an off-the-shelf trispecific antibody that co-engages BCMA and GPRC5D on myeloma cells while recruiting CD3⁺ T cells. In the first-in-human phase 1 dose-escalation/optimization trial…
NCT05652335 - Trial result
Lymphoma
Emavusertib (IRAK4i) + Ibrutinib Achieves 4/6 Deep Responses in MyD88-mutant R/R PCNSL, with CSF Levels Rising Two-fold at 200 mg BID
Emavusertib, an oral, brain-penetrant IRAK4 inhibitor, was paired with ibrutinib 560 mg QD in the phase 1/2 TakeAim‐Lymphoma trial (NCT03328078). Among seven patients with relapsed/refractory primary CNS-lymphoma who…
NCT03328078 - Trial result
Lymphoma
KITE-363 Dual-Target (CD19 + CD20) CAR-T Hits 87% ORR and 78% CR in Dose-Level-3 LBCL After ≥2 Lines
KITE-363 is an autologous bicistronic CAR-T engineered to co-recognize CD19 and CD20, aiming to head off CD19-negative relapse. In the phase 1 NCT04989803 trial, 37 heavily pre-treated large B-cell-lymphoma patients…
NCT04989803 - Trial result
Lymphoma
Brentuximab Vedotin + Nivolumab Clears ctDNA in 100% of Early-Stage Hodgkin Lymphoma by End of Therapy
In the SGN35-027 Part C Phase 2 study (NCT03646123), 36 stage I–II cHL (classic or early-state Hodgkin lymphoma) patients received brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine every 28 days. Baseline…
NCT03646123 - Trial result
Lymphoma
Acimtamig + AlloNK Delivers 86% ORR and 55% CR in Heavily Pretreated Classical Hodgkin Lymphoma
Acimtamig (AFM13) is a tetravalent CD30/CD16 innate-cell engager that redirects NK cells; AlloNK (AB-101) is an off-the-shelf cord-blood NK-cell product co-infused with IL-2. In the completed dose-finding stage of…
NCT05883449 - Trial result
Other blood cancers and transplant
Asciminib (STAMP/BCR-ABL1) pediatric formulation hits 64-67% MMR with adult-equivalent PK in Ph+ CML-CP
Asciminib, an allosteric BCR-ABL1 STAMP inhibitor, was evaluated in the Phase Ib/II ASC4Kids study (NCT04925479). Nineteen children (1–<18 y) with Philadelphia chromosome-positive Chronic Myeloid Leukemia in the…
NCT04925479 - Trial result
Other blood cancers and transplant
ASC2ESCALATE: Asciminib STAMP inhibitor clears BCR-ABL1 ≤ 1% in 83% after one prior TKI
Asciminib, an allosteric BCR-ABL1 “STAMP” inhibitor, was tested in the single-arm Phase 2 ASC2ESCALATE trial (NCT05384587) in 101 adults with chronic-phase CML who had failed or were intolerant to exactly one TKI.…
NCT05384587 - Trial result
Other blood cancers and transplant
CD7-directed allogeneic CAR-T WU-CART-007 delivers 73% complete remissions in relapsed/refractory T-ALL/LBL
WU-CART-007 is a fratricide-resistant, healthy-donor CAR-T that targets CD7. In the phase 1/2 dose-escalation/expansion trial (NCT04984356), 28 heavily pre-treated patients received a single infusion after standard…
NCT04984356 - Trial result
Head and neck cancer
TORS-Based Risk-Adapted De-Escalation Sustains 97% 5-Year OS in Early HPV-Positive Oropharyngeal Cancer
Transoral robotic surgery (TORS) followed by pathologic risk–stratified adjuvant therapy (observation n = 31, 50 Gy RT n = 15, or 56 Gy cisplatin-CRT n = 17) was evaluated in the single-arm Phase II SIRS trial…
NCT02072148 - Trial result
Head and neck cancer
Cemiplimab + platinum-docetaxel/cetuximab delivers 31% pCR, 97% 1-yr OS in resectable HNSCC
Cemiplimab, an anti-PD-1 IgG4, was added to cisplatin / carboplatin-docetaxel and EGFR-blocker cetuximab in a single-arm pilot (NCT04722523) of 30 locally advanced head-and-neck SCC patients slated for surgery and…
NCT04722523 - Trial result
Colorectal cancer
Retifanlimab + Carboplatin/Paclitaxel Cuts Risk of Progression 37% Across All Subgroups in Advanced Anal Cancer (POD1UM-303)
In the POD1UM-303 phase 3 trial (NCT04472429), 308 patients with inoperable locally recurrent or metastatic SCAC were randomised 1:1 to retifanlimab (PD-1 Ab) + carboplatin/paclitaxel or placebo + chemotherapy.…
NCT04472429 - Trial result
Melanoma
High-Dose BCNU Chemoembolization Yields 93% Disease Control in First-Line Hepatic-Dominant Uveal Melanoma
In the single-arm phase 2 (NCT04728633) trial, 28 treatment-naïve patients with <50% liver involvement and minimal extrahepatic spread received trans-arterial chemo-embolization (TACE) with 300 mg carmustine (BCNU)…
NCT04728633 - Trial result
Melanoma
Melphalan/Hepatic Delivery System Achieves 46% ORR in First-line Liver-Dominant Uveal Melanoma
Melphalan/HDS delivers high-dose alkylator directly into the hepatic artery with extracorporeal chemofiltration, aiming to control the liver—the first and often only metastatic site in uveal melanoma. In the…
NCT05022901 - Trial result
Melanoma
Tocilizumab + Ipilimumab/Nivolumab Links Lower Early Grade ≥3 irAEs (43% vs ~60%) to Th17 Dampening in Front-Line Melanoma
In the phase I/II (NCT04940299) study, 35 treatment-naïve advanced melanoma patients received ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 3 weeks plus weekly (162 mg, n = 16) or bi-weekly (n = 19) subcutaneous…
NCT04940299 - Trial result
Melanoma
Nivolumab + Relatlimab Shows 22% Intracranial Response in PD-1–Refractory Melanoma Brain Mets and likely doubles survival
Nivolumab plus relatlimab, a PD-1/LAG-3 checkpoint pair, was evaluated in the phase I/IIa RELATIVITY-020 post-hoc brain-metastasis analysis (NCT01968109). Twenty-seven heavily pre-treated patients (100% prior…
NCT01968109 - Trial result
Melanoma
Ozuriftamab Vedotin Shrinks Tumors in 4 out of 5 Refractory Melanoma Patients via ROR2-Targeted α-MMAE Delivery
Ozuriftamab vedotin is a conditionally active antibody-drug conjugate that binds the non-canonical WNT receptor ROR2 and releases MMAE preferentially in the acidic tumor milieu. In the first-in-human phase 1 study…
NCT03504488 - Trial result
Melanoma
RP1 (VSV-GM-CSF) + Nivolumab Shrinks 97% of Injected and 97% of Bystander Lesions in PD-1–Refractory Melanoma
RP1, an oncolytic vaccine armed with GM-CSF and fusogenic GALV-GP-RCT, was injected Q2W into superficial and/or image-guided visceral tumors alongside nivolumab IV (240 mg Q2W) in 140 anti-PD-1–failed melanoma…
NCT03767348 - Trial result
Sarcoma and GIST
Durvalumab (PD-L1) + doxorubicin boosts PFS to 8.2 mo in anthracycline-naïve soft-tissue sarcoma
Durvalumab, a PD-L1 inhibitor, 1500 mg plus topoisomerase II inhibitor doxorubicin 75 mg/m² Q3W was tested in the phase Ib/II NCT03798106 trial in 41 metastatic/recurrent STS patients with no prior anthracycline or…
NCT03798106 - Trial result
Thyroid cancer
Pembrolizumab + dabrafenib/trametinib drives 97% R0/R1 resections and 20-mo OS in BRAF V600E anaplastic thyroid cancer
Neoadjuvant BRAF inhibitor DTP, the combination of dabrafenib (150 mg BID) + trametinib (2 mg QD) for 3-6 weeks followed by pembrolizumab 200 mg Q3W—was tested in a multicenter phase 2 trial (NCT04675710) enrolling…
NCT04675710 - Trial result
Thyroid cancer
KL590586 RET-Targeted TKI Yields 63% ORR and 78% 2-Year PFS in Advanced Medullary Thyroid Cancer
KL590586 (A400/EP0031) is a next-generation, brain-penetrant selective RET inhibitor engineered to tackle resistance mutations. In the phase I dose-escalation/expansion KL400-I/II-01 study (NCT05265091) in China, 27…
NCT05265091 - Trial result
Acute myeloid leukemia and MDS
Bexmarilimab (Clever-1 macrophage checkpoint) + azacitidine logs 80% ORR and 13.4-mo OS in relapsed high-risk MDS
Bexmarilimab, an antibody that blocks the macrophage/blast checkpoint Clever-1, was combined with standard azacitidine in the phase 1/2 BEXMAB trial (NCT05428969). In 35 hypomethylating-agent–refractory MDS patients,…
NCT05428969 - New trial
Multiple solid tumors
Phase 1b DF6215 trial: IL-2 variant immune modulator
This open‐label study evaluates DF6215 as monotherapy and with pembrolizumab in patients with advanced solid tumors, including melanoma and ovarian cancer, to assess safety, tolerability, pharmacokinetics, and early…
NCT06108479 - New trial
Multiple solid tumors
Phase I Trial: NovoTTF-200M—Electromagnetic Therapy for Refractory Spinal Metastasis
This Phase I study at M.D. Anderson evaluates the safety of NovoTTF-200M and NovoTTF-200A devices delivering electromagnetic therapy alone or with standard treatment in patients with refractory spinal metastasis.…
NCT06906900 - New trial
Multiple solid tumors
Phase 1 study of SLV-154, small molecule inhibitor with undefined MOA.
This Phase 1 dose-escalation study by Solve Therapeutics in Saint Louis evaluates SLV-154 as a monotherapy for patients with metastatic, progressive solid tumors including SCCHN, sarcoma, breast, cervical,…
NCT06771219 - New trial
Multiple solid tumors
Phase 1/1b trial of BMS-986488, undefined MOA small molecule inhibitor.
This trial evaluates BMS-986488 as monotherapy or in combination with adagrasib, cetuximab, or nivolumab to assess safety, tolerability, and initial anti-tumor activity in patients with advanced, unresectable solid…
NCT06764771 - New trial
Multiple solid tumors
Phase I Trial of XL309, a USP1 (BRCA/HRD directed) Inhibitor in Advanced Tumors
This open-label, multicenter Phase I study led by Exelixis evaluates XL309 as a single agent and with olaparib in patients with advanced solid tumors, including HRR-mutant, CRPC, breast, pancreatic, and HGSOC…
NCT05932862
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.